These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 27581819

  • 1. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Sankpal UT, Ingersoll SB, Ahmad S, Holloway RW, Bhat VB, Simecka JW, Daniel L, Kariali E, Vishwanatha JK, Basha R.
    Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
    [Abstract] [Full Text] [Related]

  • 2. Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth.
    Shelake S, Sankpal UT, Paul Bowman W, Wise M, Ray A, Basha R.
    Invest New Drugs; 2017 Apr; 35(2):158-165. PubMed ID: 28025760
    [Abstract] [Full Text] [Related]

  • 3. Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.
    Eslin D, Lee C, Sankpal UT, Maliakal P, Sutphin RM, Abraham L, Basha R.
    Tumour Biol; 2013 Oct; 34(5):2781-9. PubMed ID: 23686785
    [Abstract] [Full Text] [Related]

  • 4. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma.
    Eslin D, Sankpal UT, Lee C, Sutphin RM, Maliakal P, Currier E, Sholler G, Khan M, Basha R.
    Mol Carcinog; 2013 May; 52(5):377-86. PubMed ID: 22213339
    [Abstract] [Full Text] [Related]

  • 5. Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.
    Sankpal UT, Nagaraju GP, Gottipolu SR, Hurtado M, Jordan CG, Simecka JW, Shoji M, El-Rayes B, Basha R.
    Oncotarget; 2016 Jan 19; 7(3):3186-200. PubMed ID: 26672603
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.
    Hurtado M, Sankpal UT, Kaba A, Mahammad S, Chhabra J, Brown DT, Gurung RK, Holder AA, Vishwanatha JK, Basha R.
    Cell Physiol Biochem; 2018 Jan 19; 51(4):1894-1907. PubMed ID: 30504717
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L, Qiu H, Zhang M, Zhang F, Yang H, Yang L, Jia L, Qin K, Jia L, Dou X, Cheng L, Sang M, Zhang C, Shan B, Zhang Z.
    Biomed Pharmacother; 2016 Apr 19; 79():166-75. PubMed ID: 27044825
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors.
    Zhang Z, Liao H, Chen X, Zheng Y, Liu Y, Tao X, Gu C, Dong L, Duan T, Yang Y, Liu X, Yu Y, Feng Y.
    Eur J Obstet Gynecol Reprod Biol; 2011 Mar 19; 155(1):69-74. PubMed ID: 21074309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.